Abstract
perceived susceptibility to HIV (r = 0.26, p < 0.001), and perceived vaccine benefits (r = 0.17, p < 0.05); and negatively associated with: cost (r = -0.33, p < 0.05), not being in a risk group (r = -0.32, p < 0.001), pragmatic obstacles (r = -0.29, p < 0.05), fear of vaccines (r = -0.20, p < 0.05), side effects/safety concerns (r = -0.16, p < 0.01), fear of needles (r = -0.12, p < 0.05), and African American ethnicity (r = -0.08, p < 0.05).
Highlights
AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
The effectiveness of a preventive vaccine in controlling the epidemic will be contingent on acceptability and access
Mean acceptability was 74.5 (SD = 9.4) at high (80–95%) versus 39.4 (SD = 21.1) at moderate (50%) efficacy (p < 0.001), reported concurrently in 10 studies
Summary
Preventive HIV vaccine acceptability: a systematic review and meta-analysis. Address: University of Toronto, Toronto, Canada * Corresponding author from AIDS Vaccine 2009 Paris, France. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P212 doi:10.1186/1742-4690-6-S3-P212. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
